
Eleanor Thomas of Emory School of Medicine served as co-principal investigator of the study.
Photo Credit: Courtesy of Emory University School of Medicine
Scientific Frontline: Extended "At a Glance" Summary: 10-Protein Biomarker Panel for ALS Detection
The Core Concept: Researchers have identified a specific combination of 10 blood proteins that can distinguish individuals with amyotrophic lateral sclerosis (ALS) from healthy individuals with nearly 98 percent balanced accuracy. This multiprotein signature provides a highly sensitive method for identifying the neurodegenerative disease using blood plasma.
Key Distinction/Mechanism: Rather than relying on a single biomarker like neurofilament light (NfL), which can also be elevated in other neurological conditions, this diagnostic panel combines multiple proteins associated with different disease mechanisms, such as nerve-cell injury and inflammation. It utilizes highly sensitive Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) technology to measure extremely small amounts of these proteins in the blood.
Major Frameworks/Components:
- Multiplex biomarker screening and profiling for neurodegenerative diseases.
- Utilization of Nucleic Acid Linked Immuno-Sandwich Assay (NULISA) technology for ultrasensitive protein detection.
- Integration of concurrent inflammatory and nerve-cell injury markers to improve diagnostic specificity over single-target assays.
.jpg)


.png)
.jpg)


.jpg)
.jpg)

.jpeg)


.png)